Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
Infectious Disease
•
Vaccines
•
Shingles vaccination
•
Allergy & Immunology
•
Primary Immunodeficiency
•
Primary Care
Would you advise an immunocompromised patient that developed a dermatomal rash after the first recombinant zoster vaccine to receive the second dose?
Related Questions
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
Is there any value to IgG subclasses in assessing immune deficiency in a patient with normal IgG levels?
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
Do you have to extend treatment for acute Lyme disease if a patient is on high dose steroids for another indication?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
